Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

Evotec Awarded Roughly $3.74 by German Government to Hunt for Neuroprotective Compounds

  • Evotec received a research grant of up to €2.5 million (about $3.74 million) from the German government to fund R&D on serine racemase, a potential target in the field of neuroprotection. The grant will fund the company’s use of its compound library and fragment-based drug discovery platform to progress the project toward the clinic.

    The money was awarded as part of Evotec’s involvement in the German government-supported Neu2 consortium. The consortium is focused on developing therapeutics against neurodegenerative diseases including multiple sclerosis.

    Partners include Evotec, Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »